REVIEW ARTICLE

JIACM 2020; 21(3-4): 151-57

Rickets in Renal Tubular Acidosis: A Clinical Appraisal

Chhavi Agrawal, Partha Pratim Chakraborty***

Abstract

Rickets, a metabolic disease restricted to an age group before epiphyseal growth plate fusion, is diagnosed by typical skeletal deformities and characteristic radiological features. The commonest aetiology of rickets worldwide is nutritional deficiency of vitamin D and/or calcium, followed by primary renal phosphate wasting disorders. Renal tubular acidosis is an important cause of rickets, particularly 'resistant rickets', as the diagnosis is often missed initially and the patients are being wrongly treated with other agents without any benefit. Renal tubular acidosis is characterised by normal anion gap metabolic acidosis and is classified into different subtypes. A systemic step-wise approach is needed in suspected patients to unveil the subtype of renal tubular acidosis and the underlying aetiology. Early diagnosis and proper management of renal tubular acidosis leads to complete clinical and radiological recovery in patients presenting with rickets secondary to renal tubular acidosis.

Key words: Rickets, renal tubular acidosis, urinary anion gap, tubular reabsorption of phosphate, tubular maximum for phosphate corrected for GFR.

Introduction

Rickets, a skeletal disorder limited to children and adolescents before epiphyseal fusion, is characterised by deficient mineralisation of the growth plate cartilages. The typical skeletal deformities and radiological abnormalities found in rickets are also associated with defective mineralisation of mature osseous matrix, a condition known as osteomalacia. Normal mineralisation of either the cartilages or the lamellar bone requires optimal calcium X phosphate product, which in turn depends on a homoeostatic system, finely regulated by vitamin D and parathyroid hormone (PTH). Three principal metabolic abnormalities found in overwhelming majority of children with rickets are defective vitamin D homoeostasis (deficiency, metabolism, and action), primary renal phosphate wasting, and calcium deficiency; hence rickets are often broadly classified as calciopenic rickets and phosphopenic rickets. While calciopenic rickets is secondary to calcium deficiency or altered vitamin D homoeostasis, phosphopenic rickets is the result of primary renal phosphate wasting, and is typically characterised by normal serum calcium and PTH[1,2]. However, it needs to be remembered that all forms of calciopenic rickets are associated with secondary hyperparathyroidism and resultant hypophosphataemia due to PTH-induced proximal renal tubular loss of phosphate. Hypophosphataemia, seen in both these forms of rickets, interferes with capase-9 mediated apoptosis of the hypertrophic chondrocytes, that ultimately gives rise to the typical clinical and radiological appearances.

Hypophosphatasia, a condition associated with deficient function of alkaline phosphatase (ALP) enzyme, chronic systemic acidosis due to any cause, and drugs like bisphosphonate, fluoride, aluminium, and parenteral iron are also associated with mineralisation defects of the cartilages and bones. Serum calcium and phosphate concentrations are usually normal in rickets secondary to these conditions. Two most common disorders associated with metabolic acidosis and rickets are chronic kidney disease and renal tubular acidosis (RTA) (Fig. 1).



Fig. 1: *A 4-year-old girl with rickets due to dRTA. Note the 'windswept' deformity (A) and wrist widening (D). Typical radiological features like cupping, splaying, fraying, and increased metaphyseal lucency are visible around the knee (B) and wrist joints (C).*

Renal tubular acidosis

RTA is a group of renal tubular disorders due to defects in proximal tubular reabsorption of bicarbonate ion (HCO_3^-), distal tubular excretion of hydrogen ion (H^+) or both, and is

****Resident, **Clinical Tutor, Department of Endocrinology and Metabolism, Medical College and Hospital, Kolkata, 88, College Street, Kolkata - 700 073, West Bengal.***

Corresponding Author: Dr Partha Pratim Chakraborty, Department of Endocrinology and Metabolism, Medical College and Hospital, Kolkata, 88, College Street, Kolkata - 700 073, West Bengal. Phone: 9830092947, E-mail: docparthapc@yahoo.co.in.

characterised by hyperchloremic normal serum anion gap (AG) metabolic acidosis in patients with relatively normal glomerular filtration rate (GFR). Lost HCO_3^- in this condition is effectively replaced by chloride ion (Cl^-), resulting in hyperchloraemia and normal AG. Patients with estimated GFR (eGFR) between 20 - 50 ml/min/1.73M^2 usually have normal AG, while those with eGFR of < 20 ml/min/1.73M^2 have high AG. Acid-base disequilibrium in RTA occurs despite a normal or only mildly reduced glomerular GFR[3]. RTA is a poorly appreciated entity among many physicians, and understanding of the pathophysiology of the disease is important for subtyping and appropriate management. It can be classified into three major forms: type 1 or distal RTA (dRTA), type 2 or proximal RTA (pRTA), and type 4 or hyperkalemic RTA. dRTA is associated with reduced H^+ secretion, pRTA is characterised by impaired HCO_3^- reabsorption, and type 4 RTA is an acid-base disturbance generated by aldosterone deficiency or resistance. RTA can occur due to primary renal pathology or secondary to a variety of systemic diseases (Table I).

Table I: Types and aetiologies of RTA.

	Primary	Secondary
Distal RTA (type 1)	Sporadic or Hereditary (Mutation of H^+K^+ ATPase, H^+ATPase, AE1)	**Autoimmune:** Sjogren's, SLE, RA, PBC **Nephrotoxins:** Amphotericn B, Trimethoprim, lithium **Miscellaneous:** Sarcoidosis, amyloidosis, obstructive uropathy
Proximal RTA (type 2)	Sporadic or Hereditary (Mutation of CA-IV, NHE-3, NBC-1)	**Autoimmune:** Sjogren's **Nephrotoxins:** tetracycline, topiramate, valproate, acetazolamide **Metabolic:** Wilson's disease, Cystinosis, Lowe's syndrome, Galactosaemia, chronic hypocalcaemia; Hereditary fructose intolerance, Tyrosinaemia **Miscellaneous:** Multiple myeloma, amyloidosis
Hyperkalemic RTA (type 4)	PHA-1, PHA-2 (Gordon's syndrome)	**Aldosterone deficiency or aldosterone resistance:** Hypoaldosteronism, ACEIs, ARBs **Hyporeninemic hypoaldosteronism:** Diabetes, Sickle cell disease Tubulointerstitial disease (eGFR: 20 - 50 ml/min) **Drugs:** Potassium sparing diuretics, NSAIDs, Trimethoprim, Pentamidine Cyclosporine, Tacrolimus
Mixed RTA (type 3)	Mutation in CA-II	Type 1 RTA with secondary proximal tubule dysfunction, Type 2 RTA with secondary distal tubule dysfunction

AE1: Anion exchanger 1; CA: Carbonic anhydrase; NHE-3: Sodium-hydrogen exchanger 3; NBC-1: Sodium-bicarbonate co-transporter 1; PHA: Pseudohypoaldosteronism; SLE: Systemic lupus erythematosus; RA: Rheumatoid arthritis; PBC: Primary billiary cirrhosis; ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker.

Free H^+, secreted from distal tubule constitute < 1% of total H^+ secreted; most protons are excreted as NH_4^+ (NH_3+H^+). dRTA is characterised by defective distal H^+ secretion, hence less urinary NH_4^+ excretion; as a result, urine pH is > 5.5, that is persistent and present during simultaneous systemic metabolic acidosis. Alkaline urine associated with hypercalciuria and hypocitraturia, often seen in dRTA, contribute to nephrocalcinosis and/or nephrolithiasis (Fig. 2)[4]. Serum potassium (K^+) is often low or normal, except when there is an underlying voltage-dependent defect, which is associated with impaired distal sodium (Na^+) transport and secondary impairment of distal K^+ secretion, leading to hyperkalaemia (hyperkalemic dRTA[5]. Hyperkalemic dRTA is different from type 4 RTA. In contrast to hyperkalemic dRTA, the ability to lower urine pH in response to systemic acidosis is maintained, and nephrocalcinosis is absent in type 4 RTA. Clinical manifestations in type 4 RTA are usually due to underlying disease, rather than RTA per se. An incomplete form of dRTA is often encountered, where patients demonstrate normal blood pH with low normal or mildly decreased serum HCO_3^- concentration, while lacking the ability to acidify urine when systemic acidosis is induced with an acidifying agent.



Fig. 2: *dRTA in a 16-year-old boy with rickets and bilateral nephrocalcinosis (C). Metaphyseal changes are seen in B.*

Proximal convoluted tubule (PCT) reabsorbs 80 - 85% of the filtered HCO_3^-, 10% is from the loop of Henle and remaining 5 - 10% is reabsorbed from collecting tubules. pRTA is characterised by impaired HCO_3^- reabsorption from PCT, i.e., a decrease in renal HCO_3^- threshold to 14 - 18 mmol/l, which is normally ~ 22 mmol/l in infants, and 25 -

26 mmol/l in children and adults[6]. Metabolic acidosis in pRTA tends to be milder because distal HCO_3^- reclamation remains intact and bicarbonaturia disappears when serum HCO_3^- concentration falls below the HCO_3^- tubular maximum (often at serum HCO_3^- level of 14 - 18 mmol/l). Urine pH in pRTA is variable; alkaline (> 5.5), if serum HCO_3^- concentration is above the threshold, and < 5.5 when serum HCO_3^- is below the threshold. pRTA may be isolated, or more commonly associated with Fanconi syndrome, a form of generalised proximal tubular dysfunction. Fanconi syndrome is a malabsorptive state of the PCT, wherein absorption of glucose, amino acids, low molecular weight proteins, phosphates, potassium, bicarbonate and uric acid are impaired; while pRTA refers to the deficiency in HCO_3^- retention only. Despite hypercalciuria, nephrocalcinosis/nephrolithiasis are infrequent, due to acidic urine and absence of hypocitraturia[7].

Type 3 RTA shares features of both type 1 (dRTA) and 2 (pRTA). Carbonic anhydrase II (CA-II) deficiency, either inherited or acquired, presents with features of both pRTA and dRTA along with osteopetrosis, cerebral calcification and mental retardation due to deficiency of the enzymes in various organs[8]. Other conditions likely to be associated with type 3 RTA are acetazolamide use, Wilson disease, hereditary fructose intolerance and dysproteinemic syndromes. More commonly however, this pattern is observed as a transient phenomenon, when biochemical abnormalities arising out of dRTA (acidosis, hypokalaemia) induce proximal tubular dysfunction or metabolic alterations associated with pRTA (hypophosphataemia) impair distal tubular acidification mechanisms, thus contributing to a mixed phenotype of type 3 RTA[9,10].

In children and adolescents, RTA may present with failure to thrive, growth retardation, hypokalaemia, polyuria and polydipsia (due to defective urinary concentrating ability), nephrocalcinosis/nephrolithiasis (dRTA), and 'refractory rickets'. The definition of refractory rickets is not universally accepted; however, absence of radiological healing lines after 3 - 4 weeks of adequate calcium and vitamin D suggests non-nutritional rickets. An approach to such cases has been summarised in Fig. 3. Rickets and osteomalacia are common in dRTA and relatively uncommon in pRTA, unless associated significant acidosis and/or hypophosphataemia, as encountered in Fanconi syndrome. Features of rickets/osteomalacia are usually absent in incomplete dRTA and type 4 RTA unless the later is associated with uraemia.

Rickets in RTA

Rickets in RTA is multifactorial. Systemic acidosis is associated with defective mineralisation of the cartilages and bones due to increased solubility of the mineral phase. During acidosis, calcium and phosphate are mobilised from bones for the purpose of buffering by enhanced osteoclastic resorption. Enhanced osteoclastic activity results in influx of calcium and phosphate into the circulation. These molecules are subsequently lost through kidneys due to increased filtered load and reduced proximal tubular reabsorption secondary to systemic acidosis. Hypercalciuria results in secondary hyperparathyroidism that further aggravates hypophosphataemia due to renal phosphate loss. In addition, pRTA itself may be associated with phosphaturia and low renal 1α-hydroxylase activity, which leads to



Fig. 3: *Approach to refractory rickets.*

impaired conversion of 25-hydroxy vitamin D to calcitriol (1, 25-dihydroxy vitamin D), the active form of vitamin D.

Approach

A thorough clinical survey of the child with rickets focussing the peripheral extremities, cranium, spine and eyes is of utmost importance. The authors recommend measurement of serum calcium, phosphate, albumin, ALP, PTH (by second generation assay), 25-hydroxy vitamin D, creatinine and arterial blood gas analysis at baseline in all children with rickets. Corrected serum calcium, then should be calculated using the formula:

Corrected Calcium = measured Calcium + 0.8 X (4 - serum Albumin).

Absolute value of creatinine may be misleading in children; hence eGFR should be calculated using the Schwartz formula to rule-out chronic kidney disease.

In patients with metabolic acidosis, the next step is measurement of serum AG [AG = $Na^+ - (Cl^- + HCO_3^-)$] and then calculation of albumin corrected AG using the formula: corrected AG = calculated AG + 2.4 X (4 - serum albumin). Wide reference ranges of 3.0 - 12 mmol/l to 8.5 - 15 mmol/l for the AG have been reported owing to difference in laboratory methods[11]. The authors use a reference range of

12 ± 4 mmol/l; however, clinician, should use their laboratory specific reference ranges.

Gastrointestinal (GI) loss of HCO_3^- due to diarrhoea, external pancreatic/small bowel drainage, ureterosigmoidostomy, jejunal loop and drugs like calcium chloride, magnesium sulphate, and cholestyramine simulate RTA due to presence of hyperchloremic normal AG metabolic acidosis. Urinary AG (UAG) measurement is the next step; GI loss of HCO_3^- is associated with negative UAG, while positive UAG suggests RTA[12]. UAG is calculated by the formula: UAG = Urine [(Na^+ + K^+) – Cl^-]. A true AG, however, does not exist *in vivo* (serum or urine), since the sum of positive and negative ion charges must be equal. For an example, in urine, ($Na^+ + K^+ + NH_4^+$ + unmeasured cations) = (Cl^- + unmeasured anions).

The difference between urinary unmeasured anions (sulfates, phosphates, organic anions) and unmeasured cations (calcium, magnesium) is relatively constant at an approximate value of 80, therefore urinary $Na^+ + K^+ + NH_4^+ = Cl^- + 80$, or $NH_4^+ = 80 – UAG$, or $UAG = 80 – NH_4^+$[13]. The equation, that is utilised to have an estimate of urinary NH_4^+ excretion, and numerically not much different from the above formula is urinary NH_4^+ = 82 " 0.8 X UAG[14]. Positive UAG suggests more unmeasured anions (SO_4^{2-}, PO_4^{3-}) and minimal or no NH_4^+ likely due to RTA, while a negative UAG suggests adequate urinary NH_4^+ due to preserved urinary acidification system, hence GI loss of HCO_3^-. In summary, positive UAG (~ +20 to +90) in a background of normal AG metabolic acidosis is encountered in dRTA and pRTA when serum HCO_3^- is below threshold (14 - 18 mmol/l). On the other hand, a negative UAG (~ -20 to -50) suggests GI loss of HCO_3^- or pRTA with HCO_3^- above threshold (14 - 18 mmol/l).

However, there are certain limitations to the use of UAG[15,16,17,18].

1. UAG is of limited use if value falls between -20 and +20.
2. UAG is unreliable when urine pH exceeds 6.5. Urine pH of more than 6.5 suggests significant urinary HCO_3^-, an anion that is not taken into consideration while calculating UAG.
3. When anions other than Cl^-, such as β-hydroxybutyrate or acetoacetate in ketoacidosis, hippurate in toluene intoxication, acetylsalicylic acid, D-lactic acid and large quantities of penicillin are excreted in the company of NH_4^+, the value for NH_4^+derived using the UAG will significantly underestimate the actual urinary NH_4^+ excretion. However, all these conditions are associated with high AG metabolic acidosis, and should not be confounding UAG in RTA. Increased unmeasured urinary cations like lithium may also interfere with UAG interpretation at times.
4. Acidification of urine requires adequate distal delivery of sodium. So, when distal Na^+ delivery is impaired, as suggested by urinary $Na^+ < 20$ - 25 mmol/l, usefulness of UAG is questionable.

In these above situations urine osmolar gap (UOG) is an effective alternative:

UOG = measured U_{osm}- calculated U_{osm}. Calculated U_{osm} = 2 X (serum [$Na^+ + K^+$] in mmol/l) + [blood urea nitrogen (in mg/dl)]/2.8 + [glucose (in mg/dl)]/18.

Modified UOG or UOG/2 is likely a true estimate of urinary NH_4^+, as it reflects the contribution of the anions accompanying NH_4^+ to the osmolality[19]. Urinary NH_4^+ of ≥ 75 mmol/l suggests intact NH_4^+secretion, while urinary $NH_4^+$of ≤ 25 mmol/l points towards inappropriately low NH_4^+secretion. Some authors have suggested that UOG less than 40 mmol/l in patients with normal AG metabolic acidosis indicates impaired urinary NH_4^+ excretion, while urinary NH_4^+ is considered appropriately increased if the gap is above 100[11,13]. To summarise, UOG of less than 40 - 50 mmol/l in a background of normal AG metabolic suggests dRTA and UOG of more than 100 - 150 mmol/l points against dRTA.

Once the diagnosis of RTA is established, the next step is to identify its type. Freshly voided early morning, uninfected (urea spitting organisms are associated with falsely high urine pH) urine sample is tested for urine pH, a marker of urinary free H^+ concentration, preferably with a pH meter. Urine should ideally be collected under mineral oil to prevent dissipation of CO_2 and falsely elevated urine pH. Minimum achievable urine pH with normal renal function and acidification is 4.5 - 5.3. Urine pH > 5.5 in the presence of metabolic acidosis can be due to dRTA or pRTA with serum HCO_3^- above threshold or pRTA being treated with alkali. A filtered HCO_3^- that exceeds PCT reabsorptive capacity shall give falsely high urine pH. Urine pH < 5.5 during metabolic acidosis suggests pRTA with serum HCO_3^- below threshold. Metabolic acidosis and hypokalaemia associated with diarrhoea may increase renal NH_3 synthesis. In presence of normal distal tubular H^+ secretion, more renal NH_4^+ is produced, hence urine pH becomes alkaline (> 5.5) in diarrhoea. So, urine pH should always be performed once GI loss of HCO_3^- is ruled-out with negative UAG or high UOG. Urinary Na^+ less than 20 - 25 mmol/l is associated with low distal tubular H^+ secretion, hence, falsely high urine pH. A suggested approach to normal AG metabolic acidosis has been summarised in Fig. 4.

Other tests, that are used to assess distal acidification defects in patients of incomplete dRTA are ammonium chloride (NH_4Cl) challenge test, calcium chloride challenge test, frusemide plus fludrocortisone test and measurement of pCO_2 difference between urine and blood after $NaHCO_3$



Fig. 4: *Approach to metabolic acidosis.*

infusion[20,21]. However, these tests are not required in a child with rickets secondary to RTA, as metabolic acidosis is florid in such cases.

pRTA is recognised by requirements for large quantities of base to raise serum HCO_3^- and appearance of bicarbonaturia at a normal serum HCO_3^- concentration. pRTA in steady state is associated with metabolic acidosis (HCO_3^-: 14 - 18 mmol/l), acidic urine pH (< 5.5) and low fractional HCO_3^- excretion (Fe-HCO_3). Fe-HCO_3 of more than 15 - 20% and urine pH higher than 7.5, when serum HCO_3^- is raised to normal values following infusion of $NaHCO_3$ confirms pRTA[22].

Type 3 RTA was formerly thought to be more widespread, when first identified. Infants with dRTA were routinely found to possess co-existing significant urinary HCO_3^- wasting. It is now acknowledged that most young children with dRTA experience an initial transient phase of bicarbonaturia as part of the syndrome's natural history. The precise mechanism(s) of proximal tubular dysfunction in dRTA is yet to be crystallised and two potential explanations have been put forward. Intracellular acidosis secondary to systemic acidosis induces endosomal dysfunction in proximal tubular cells in dRTA and results in proximal renal tubular cell dysfunction. Chronic hypokalaemia also induces a number of pathological changes in renal proximal tubular cells (infiltration with inflammatory mononuclear cells, vacuolisation, atrophy, destruction, brush border damage or even interstitial fibrosis) that culminates into proximal tubular dysfunction.

Unlike other forms of rickets, hypophosphataemia is uncommon in rickets associated with RTA. In a patient of hypophosphataemia, renal loss of phosphate should be differentiated from non renal cause of phosphate wasting by calculating tubular reabsorption of phosphate (TRP) and tubular maximum for phosphate corrected for GFR (TmP/GFR). Phosphate reabsorption occurs mainly in the PCT, which reclaim roughly 80 - 85% of the filtered load. Additional 8 - 10% phosphate is reabsorbed in the distal tubule (but not in loop of Henle), leaving about 10 - 12% for excretion in the urine. The normal TRP, therefore, is about 90%[23]. TRP is calculated using the formula 1-[(Up/Sp) X (Scr/Ucr)] (U: urine; S: serum; p: phosphate; cr: creatinine).

TmP/GFR is maximum renal tubular phosphate reabsorption in mass per unit volume of glomerular filtrate. It is independent of the rate of phosphate flow into the extracellular space from gut, cells and bone and glomerular filtration rate[24]. It was initially developed to differentiate hypercalcaemia due to hyperparathyroidism from other causes of hypercalcaemia that is now done by measuring

PTH levels[25]. If TRP is less than or equal to 0·86 then TmP/GFR can be derived from standardised nomogram or multiplying TRP by serum phosphate. If TRP is greater than 0·86, Kenny and Glen's equation is used ['x' = (0·3 X TRP)/{1-(0.8 X TRP)}] and TmP/GFR= 'x' X serum phosphate][26,27]. TmP/GFR is compared with age and sex specific range and normal value roughly corresponds with age and specific reference range for plasma phosphate. Low TmP/GFR in presence of hypophosphatemia suggests renal phosphate loss[28]. Hypophosphatemia in RTA is secondary to renal loss, and likely due to pRTA. The affected child often has co-existent glycosuria, aminoaciduria, low-molecular weight proteinuria, hypercalciuria, uricosuria in varying combinations as a part of Fanconi syndrome. However, as discussed earlier, primary dRTA is also associated with reversible form of generalised defects in proximal tubular absorptive capacity resulting in phosphaturia, low molecular proteinuria, but, not glycosuria. Moreover primary hypophosphatemic rickets or calciopenic rickets, by virtue of severe hypophosphatemia, may result in impaired HCO_3^- reabsorption from PCT (pRTA) or acquired, reversible distal acidification defect (dRTA). In addition to hypophosphatemia, secondary hyperparathyroidism associated with rickets associated with abnormal vitamin D homeostasis, also contribute to pRTA as PTH inhibits proximal tubular bicarbonate reabsorption by interfering with the activities of apical Na^+/H^+ exchanger (NHE3) and the basolateral Na^+/K^+-ATPase. Clinicians need to be vigilant to identify the underlying primary aetiology in children with rickets, normal AG metabolic acidosis and hypophosphatemia.

Once the type of RTA is identified in a child with rickets, next step is to rule out important secondary causes and mutational analysis for genes responsible for primary forms of RTA (Table I). At times, certain clinical clues may help to target specific genes for analysis. Accompanying features of CA-II mutation has already been discussed. In addition, eye changes and basal ganglion calcification in pRTA suggests NBC-1 defect, sensori-neural deafness in dRTA points towards H^+ ATPase abnormality, haemolysis with dRTA suggests defective AE1 (Table I). pRTA combined with epilepsy and osteopetrosis suggests involvement of the renal chloride channel (CLCN) gene 7 (CLCN7). Dent's disease, an X-linked condition due to defective renal CLCN5, is associated with vitamin A-responsive night blindness, hypophosphatemic rickets and generalised PCT dysfunction, and closely mimics pRTA[29]. Recently, a second variant of Dent's disease (Dent 2) due to mutation of oculocerebrorenal syndrome of Lowe gene 1(OCRL1) has been identified[30].

Treatment

Alkali replacement is the mainstay of therapy in all forms of RTA with rickets. 1 - 1.5 mEq/Kg of non-volatile acids are generated normally per day that is excreted in the form of



Fig. 5: *4.5-year-old girl with dRTA was treated with alkali therapy. Note the complete clinical (B) and radiological (D) recovery after 1.5 years of treatment. A and C represent features at presentation.*



Fig. 6: *Residual deformity after 3 years of alkali therapy in a boy diagnosed with dRTA at 16 years of age. The growth plates are fused and the boy is posted for corrective osteotomy.*

titrable acids/NH_4^+). Daily alkali requirement in RTA should take into account the H^+ retained each day and urinary bicarbonate loss, which however is negligible in dRTA. The usual daily dose of alkali in dRTA is 1 - 2 mmol/Kg in adults and 4 - 8 mmol/Kg in children. Rapidly growing skeleton generates additional acid load in children. In addition, higher fixed urine pH in children is associated with relatively larger urinary bicarbonate loss compared to adults. Sodium bicarbonate or sodium citrate is often used and titrated to achieve and maintain normal serum HCO_3^- (22 - 24 mmol/l). Correction of acidosis reduces urinary K^+ and prevents hypokalemia, and patients may not require potassium supplementation in the long run. However, in presence of hypokalemia, potassium citrate is preferred.

In contrast, owing to marked urinary HCO_3^- loss in pRTA, daily alkali requirement is much higher, 10 - 30 mmol/Kg, along with large supplementation of K^+. Increased distal tubular Na^+ and HCO_3^- delivery stimulates K^+ secretion, hence, potassium citrate with/without sodium bicarbonate is the preferred form of therapy. Near normal HCO_3^- in children needs to be achieved. If large dose of alkali is ineffective to achieve target HCO_3^- or such a high dose is not tolerated, thiazide diuretics may be added. Mild volume depletion associated with thiazide diuretics enhances Na^+ and HCO_3^- absorption in PCT. Those with severe hypophosphatemia should be co-prescribed phosphate supplement and active vitamin D metabolites.

Conclusions

RTA is a complex disease and, at times, difficult to diagnose due to the variable presentation. RTA is known to be associated with rickets, and RTA needs to be ruled-out in all cases of 'refractory rickets'. Arterial blood gas analysis is recommended at baseline in children with rickets along with other first-line investigations. Evaluation for RTA begins with measuring serum AG in individuals having metabolic acidosis. Patients with normal AG metabolic acidosis should undergo testing for UAG with/without UOG. Once the cause is established to be due to RTA, urine pH can guide for confirming the specific type of RTA. Early recognition and specific management is rewarding as it enables relief of symptoms and complete clinical and radiological remission (Fig. 5). If diagnosed late, deformity might be permanent, once growth plates are fused, that ultimately require corrective osteotomy.

References

1. Misra M, Pacaud D, Petryk A *et al*. Drug and Therapeutics Committee of the Lawson Wilkins Paediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. *Pediatrics* 2008; 122 (2): 398-417.
2. Sahay M. Homeostasis and disorders of calcium, phosphorus and magnesium. In: Vijaykumar M, Nammalwar BR, Eds. Principles and practice of pediatric nephrology. 2nd edition. New Delhi: Jaypee Brothers Medical Publishers, 2013; 82.
3. Yaxley J, Pirrone C. Review of the Diagnostic Evaluation of Renal Tubular Acidosis. *Ochsner J* 2016; 16 (4): 525-30.
4. Soleimani M, Rastegar A. Pathophysiology of Renal Tubular Acidosis: Core Curriculum 2016. *Am J Kidney Dis* 2016; 68 (3): 488-98.
5. Batlle D, Flores G. Underlying defects in distal renal tubular acidosis: new understandings [published correction appears in Am J Kidney Dis 1997 May; 29 (5): 815. *Am J Kidney Dis* 1996; 27 (6): 896-915.
6. Igarashi T, Sekine T, Inatomi J *et al*. Unraveling the molecular pathogenesis of isolated proximal renal tubular acidosis. *J Am Soc Nephrol* 2002; 13 (8): 2171-7.
7. Brenner RJ, Spring DB, Sebastian A *et al*. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. *N Engl J Med* 1982; 307 (4): 217-21.
8. Sly WS, Hewett-Emmett D, Whyte MP *et al*. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proceedings of the National Academy of Sciences of the United States of America. 1983; 80 (9): 2752-6.
9. Rodriguez-Soriano J, Vallo A, Castillo G *et al*. Natural history of primary distal renal tubular acidosis treated since infancy. *J Pediatr* 1982; 101 (5): 669-76.
10. Agrawal SS, Mishra CK, Agrawal C *et al*. *BMJ Case Rep* 2020; 13: e233350.
11. Berend K, de Vries AP, Gans RO. Physiological approach to assessment of acid-base disturbances. *N Engl J Med* 2014; 371 (15): 1434-45.
12. Kraut JA, Madias NE. Differential diagnosis of nongap metabolic acidosis: value of a systematic approach. *Clin J Am Soc Nephrol* 2012; 7 (4): 671-9.
13. Bagga A, Sinha A. Evaluation of renal tubular acidosis. *Indian J Pediatr* 2007; 74 (7): 679-86.
14. Goldstein MB, Bear R, Richardson RM *et al*. The urine anion gap: a clinically useful index of ammonium excretion. *Am J Med Sci* 1986; 292 (4): 198-202.
15. Carlisle EJ, Donnelly SM, Vasuvattakul S *et al*. Glue-sniffing and distal renal tubular acidosis: sticking to the facts. *J Am Soc Nephrol* 1991; 1 (8): 1019-27.
16. Halperin ML, Kamel KS. Some observations on the clinical approach to metabolic acidosis. *J Am Soc Nephrol* 2010; 21 (6): 894-7.
17. Halperin ML, Kamel K. Approach to the patient with metabolic acidosis: Newer concepts. *Nephrology (Carlton)* 1996; 2: S122-S127.
18. Batlle DC, von Riotte A, Schlueter W. Urinary sodium in the evaluation of hyperchloremic metabolic acidosis. *N Engl J Med* 1987; 316 (3): 140-4.
19. Dyck RF, Asthana S, Kalra J *et al*. A modification of the urine osmolal gap: an improved method for estimating urine ammonium. *Am J Nephrol* 1990; 10 (5): 359-62.
20. Walsh SB, Shirley DG, Wrong OM *et al*. Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride. *Kidney Int* 2007; 71 (12): 1310-6.

21. Kim S, Lee JW, Park J *et al*. The urine-blood PCO gradient as a diagnostic index of H(+)-ATPase defect distal renal tubular acidosis. *Kidney Int* 2004; 66 (2): 761-7.
22. Santos F, Ordóñez FA, Claramunt-Taberner D *et al*. Clinical and laboratory approaches in the diagnosis of renal tubular acidosis. *Pediatr Nephrol* 2015; 30 (12): 2099-2107.
23. Bringhurst FR, Demay MB, Kronenberg HM. Hormones and Disorders of Mineral Metabolism. In Melmed S, Auchus RJ, Goldfine AB eds. William's Textbook of Endocrinology. 14th edition. Philadelphia: Elsevier 2020; 1196-1255.
24. Bijvoet OL, Morgan DB, Fourman P. The assessment of phosphate reabsorption. *Clin Chim Acta* 1969; 26 (1): 15-24.
25. Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. *Ann Clin Biochem* 1998; 35 (Pt 2): 201-6.
26. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. *Lancet* 1975; 2 (7929): 309-10.
27. Chong WH, Molinolo AA, Chen CC *et al*. Tumor-induced osteomalacia. *Endocr Relat Cancer* 2011; 18 (3): R53-R77.
28. Imel EA, Econs MJ. Approach to the hypophosphatemic patient. *J Clin Endocrinol Metab* 2012; 97 (3): 696-706.
29. Sethi SK, Ludwig M, Kabra M *et al*. Vitamin A responsive night blindness in Dent's disease. *Pediatr Nephrol* 2009; 24 (9): 1765-70.
30. Bökenkamp A, Ludwig M. The oculocerebrorenal syndrome of Lowe: an update. *Pediatr Nephrol* 2016; 31 (12): 2201-12.